Retour aux projets

16003.1 PFLS-LS

SwissBody-enabled small molecule drug discovery for neurotransmitter/ion transporters and G protein-coupled receptors.

Résumé

SwissBody-enabled small molecule drug discovery for neurotransmitter/ion transporters and G protein-coupled receptors.

Textes supplémentaires

Abstract

Neurotransmitter/ion transporters and G protein-coupled receptors are druggable targets, but are suffering from a very high compound attrition rate. Recently, biophysical assays and structure-based drug design have enabled to overcome this hurdle but their development is time-consuming. Now, we aim at improving this process using synthetic camelid single domain antibody fragments (SwissBodies). In a novel and fast procedure we generate tailored SwissBodies to accelerate the development of novel biophysical tools and reduce compound attrition rates.

Participants

Roger Dawson

Wirtschaftspartner

Roger.dawson@roche.com

Hoffmann-La Roche AG Roger Dawson Grenzacherstrasse 124 4070 Basel BS CH

Markus Seeger

Kontaktperson

m.seeger@imm.uzh.ch

Universität Zürich Markus Seeger Gloriastrasse 30/32 8006 Zürich ZH CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2014-04-30
Date de fin
2017-08-31
Coûts totaux approuvés
CHF 715596.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%